Dr. Charlotta Agaton received her M.Sc. in Molecular Biology from Stockholm University, Sweden, and her Ph.D. in Biotechnology from the The Royal Institute of Technology, Stockholm, Sweden. The development of the HPA project was the central theme in Dr. Agaton's thesis. Today she works with product and application development at Atlas Antibodies in Stockholm.